Page last updated: 2024-12-11
verrucosidin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
verrucosidin: tremorgenic mycotoxin; structure given in first source; RN given refers to (1alpha,2alpha(1E(2S*,3R*),3E),4alpha,5alpha)-(+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6437365 |
| CHEMBL ID | 512656 |
| SCHEMBL ID | 846397 |
| MeSH ID | M0138871 |
Synonyms (9)
| Synonym |
|---|
| verrucosidin |
| CHEMBL512656 |
| 4-methoxy-3,5-dimethyl-6-[(2r,3s)-2-methyl-3-[(2e,4e)-4-methyl-5-[(1s,2s,4r,5r)-2,4,5-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-2-yl]penta-2,4-dien-2-yl]oxiran-2-yl]pyran-2-one |
| d-altritol, 2,5:3,4-dianhydro-1,6-dideoxy-2-c-((1e,3e)-4-((2s,3r)-3-(4-methoxy-3,5-dimethyl-2-oxo-2h-pyran-6-yl)-3-methyloxiranyl)-2-methyl-1,3-pentadienyl)-4-c-methyl- |
| 88389-71-3 |
| 2h-pyran-2-one, 6-(3-(1,3-dimethyl-4-(2,4,5-trimethyl-3,6-dioxabicyclo(3.1.0)hex-2-yl)-1,3-butadienyl)-2-methyloxiranyl)-4-methoxy-3,5-dimethyl-, (1s-(1alpha,2alpha(1e(2s*,3r*),4alpha,5alpha)))- |
| SCHEMBL846397 |
| Q15427942 |
| DTXSID701045464 |
Research Excerpts
Overview
Verrucosidin is a tremorgenic mycotoxin responsible for neurological diseases. It has been detected in different dry-ripened foods as consequence of the growth of toxigenic molds.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Verrucosidin, which is a tremorgenic mycotoxin responsible for neurological diseases, has been detected in different dry-ripened foods as consequence of the growth of toxigenic molds. " | ( Duplex real-time PCR method with internal amplification control for quantification of verrucosidin producing molds in dry-ripened foods. Andrade, MJ; Córdoba, JJ; Rodríguez, A; Rodríguez, M; Werning, ML, 2012) | 2.04 |
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Verrucosidinol has a ring-opened ethylene oxide moiety in the polyene α-pyrone skeleton, and verrucosidinol acetate is its acetate derivative." | ( Verrucisidinol and verrucosidinol acetate, two pyrone-type polyketides isolated from a marine derived fungus, Penicillium aurantiogriseum. Chen, C; Dai, H; Ren, B; Song, F; Sun, J; Wei, J; Yu, K; Zhang, L, 2010) | 1.41 |
| "Verrucosidinol has a ring-opened ethylene oxide moiety in the polyene α-pyrone skeleton, and verrucosidinol acetate is its acetate derivative." | ( Verrucisidinol and verrucosidinol acetate, two pyrone-type polyketides isolated from a marine derived fungus, Penicillium aurantiogriseum. Chen, C; Dai, H; Ren, B; Song, F; Sun, J; Wei, J; Yu, K; Zhang, L, 2010) | 1.41 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Verrucosidin appeared to have the highest toxic potential, testing positive in both assays." | ( Genotoxicity assessment of five tremorgenic mycotoxins (fumitremorgen B, paxilline, penitrem A, verruculogen, and verrucosidin) produced by molds isolated from fermented meats. Fink-Gremmels, J; Nijmeijer, S; Sabater-Vilar, M, 2003) | 1.44 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID338666 | Toxicity in ip dosed mouse | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.96) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (6.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||